Enjaymo

Active Ingredient(s): Sutimlimab-jome
FDA Approved: * February 4, 2022
Pharm Company: * BIOVERATIV THERAPEUTICS INC

Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD).[1][2][3] It is given by intravenous infusion.[1] Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro.[4] This drug is being developed by Bioverativ, a Sanofi company.[5] Sutimlimab was approved for medical use in the United Stat... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.